A Brett Hauber (Brett Hauber)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 23

Top Topics

Rheumatoid Arthritis

Ankylosing Spondylitis

Respiratory Syncytial Virus

Cross Sectional

Top Venues

MDM policy & practice

This page only lists publications with an associated author ORCID identifier.

Publications

Kathleen M Beusterien, Amy W Law, Martine C Maculaitis, Oliver Will, Lewis Kopenhafer, Patrick Olsen, A Brett Hauber, Jeffrey T Vietri, Joseph C Cappelleri, Joshua R Coulter, Kimberly M Shea
Healthcare Providers' and Pregnant People's Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus. Vaccines 12 (5) (2024)
Kathleen M Beusterien, Amy W Law, Martine C Maculaitis, Oliver Will, Lewis Kopenhafer, Patrick Olsen, A Brett Hauber, Jeffrey T Vietri, Joseph C Cappelleri, Joshua R Coulter, Kimberly M Shea
Healthcare Providers' and Pregnant People's Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus. Vaccines 12 (5) (2024)
Cathy Anne Pinto, Tommi Tervonen, Aura Cecilia Jimenez-Moreno, Bennett Levitan, Montse Soriano Gabarró, Cynthia J Girman, Josephine M Norquist, A Brett Hauber
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey. The patient (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Tommi Tervonen, Chiara Whichello, Ernest Law, Jonathan Mauer, Debanjali Mitra, Myrto Trapali, Nicolas Krucien, A Brett Hauber
Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment. The Journal of dermatology (2023)
Maggie Jalowsky, A Brett Hauber, Mariah Jacqueline Scott, Steven Arkin, Joshua R Coulter, Stephen J Watt, L Mariah G Kelly, Ashley Valentine
Priority Outcomes in Sickle Cell Disease Treatment: Co-Creation and Implementation of a Preference Exercise With Patients and Caregivers to Inform Drug Development. Journal of patient experience 10 (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Jonathan Mauer, Kristin Bullock, Stephen Watt, Ed Whalen, Leo Russo, Rod Junor, John D Markman, A Brett Hauber, Tommi Tervonen
Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis. British journal of clinical pharmacology 88 (8) (2022)
Marco Boeri, A Brett Hauber, Joseph Christopher Cappelleri
Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights. PharmacoEconomics 40 (7) (2022)
Douglas Barthold, Aaron T Brah, Susan M Graham, Jane M Simoni, A Brett Hauber
Improvements to Survey Design from Pilot Testing a Discrete-Choice Experiment of the Preferences of Persons Living with HIV for Long-Acting Antiretroviral Therapies. The patient 15 (5) (2022)
A Brett Hauber, Brennan Mange, Mo Zhou, Shomesh Chaudhuri, Heather L Benz, Brittany Caldwell, John P Ruiz, Anindita Saha, Martin Ho, Stephanie Christopher, Dawn Bardot, Margaret Sheehan, Anne Donnelly, Lauren McLaughlin, Katrina Gwinn, Andrew Lo, Murray Sheldon
Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. MDM policy & practice 6 (1) (2021)
Jessie Sutphin, Rachael L DiSantostefano, Colton Leach, A Brett Hauber, Carol Mansfield
Exploring Decisional Conflict With Measures of Numeracy and Optimism in a Stated Preference Survey. MDM policy & practice 6 (2) (2021)
Heather L Benz, Brittany Caldwell, John P Ruiz, Anindita Saha, Martin Ho, Stephanie Christopher, Dawn Bardot, Margaret Sheehan, Anne Donnelly, Lauren McLaughlin, Brennan Mange, A Brett Hauber, Katrina Gwinn, William J Heetderks, Murray Sheldon
Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease. MDM policy & practice 6 (1) (2021)
Åsa Grauman, Mats Hansson, Stefan K James, A Brett Hauber, Jorien Veldwijk
Communicating Test Results from a General Health Check: Preferences from a Discrete Choice Experiment Survey. The patient 14 (5) (2021)
Marco Boeri, Anna G Purdum, Jessie Sutphin, A Brett Hauber, James A Kaye
CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion. Future oncology (London, England) 17 (34) (2021)
A Brett Hauber, John R Penrod, David Gebben, Lina Musallam
The Value of Hope: Patients' and Physicians' Preferences for Survival in Advanced Non-Small Cell Lung Cancer. Patient preference and adherence 14 (2020)
Meredith Y Smith, Janine Astrid van Til, Rachael L DiSantostefano, A Brett Hauber, Kevin Marsh
Quantitative Benefit-Risk Assessment: State of the Practice Within Industry. Therapeutic innovation & regulatory science 55 (2) (2020)